Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Daniel C. Scullin"'
Autor:
F. Anthony Greco, Lisa H. Morrissey, Denise A. Yardley, Howard A. Burris, Steven W. Corso, Daniel C. Scullin, Sharlene Litchy, John D. Hainsworth
Publikováno v:
Journal of Clinical Oncology. 20:4261-4267
PURPOSE: To evaluate response to single-agent rituximab in patients with indolent non-Hodgkin’s lymphoma (NHL) and no previous systemic therapy, and the feasibility, toxicity, and efficacy of maintenance rituximab, administered at 6-month intervals
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba7bc291da7213c8a4cf8ac2fbc058c9
https://doi.org/10.1200/jco.2002.08.674
https://doi.org/10.1200/jco.2002.08.674
Autor:
Daniel C. Scullin, Gerry Ann Houston, Howard A. Burris, F. Anthony Greco, James R. Gray, H B S Lisa Morrissey, Edgar F. Prasthofer, John D. Hainsworth
Publikováno v:
Cancer. 94:2426-2433
BACKGROUND The objective of this study was to evaluate the feasibility, toxicity, and efficacy of a novel three-drug regimen containing paclitaxel, carboplatin, and topotecan followed by oral etoposide in the first-line treatment of patients with sma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d13f9655fe80c495525e1844d11cb69
https://doi.org/10.1002/cncr.10508
https://doi.org/10.1002/cncr.10508
Autor:
Lisa H. Morrissey, John H. Barton, Sharlene Litchy, Daniel C. Scullin, John D. Hainsworth, Howard A. Burris, Joan B. Erland, Paul Richards, F. Anthony Greco, James E. Bradof
Publikováno v:
Journal of Clinical Oncology. 20:1651-1656
PURPOSE: To evaluate the efficacy and toxicity of the novel chemotherapy combination that includes gemcitabine, carboplatin, and paclitaxel in the treatment of patients with carcinoma of unknown primary site. PATIENTS AND METHODS: One hundred twenty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3313f85212549dd168c9f2f5869193c
https://doi.org/10.1200/jco.2002.20.6.1651
https://doi.org/10.1200/jco.2002.20.6.1651
Autor:
Sharlene Litchy, F. Anthony Greco, Daniel C. Scullin, Paul Richards, John D. Hainsworth, Lisa H. Morrissey, Howard A. Burris, James D. Bearden
Publikováno v:
Blood. 95:3052-3056
Rituximab, a chimeric antibody that targets CD20+ B cells, produces a 48% response rate in patients with refractory low-grade non-Hodgkin lymphoma. In this phase II trial, patients with low-grade non-Hodgkin lymphoma who had previously received no sy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::233aa0db3d75de68925b577cda4d919a
https://doi.org/10.1182/blood.v95.10.3052.010k30_3052_3056
https://doi.org/10.1182/blood.v95.10.3052.010k30_3052_3056
Autor:
Jeremy K. Hon, L A Kalman, Daniel C. Scullin, Howard A. Burris, A. A. Meluch, Joan B. Erland, John D. Hainsworth, Steven W. Smith, Lisa H. Morrissey, F. Anthony Greco
Publikováno v:
Cancer. 85:1269-1276
BACKGROUND The combination of paclitaxel and carboplatin is widely used in the treatment of patients with advanced nonsmall cell lung carcinoma. In this Phase I/II study the authors evaluated the feasibility, toxicity, and efficacy of adding a third
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::491b2039e20cfae61de4ec6869a7c2fd
https://doi.org/10.1002/(sici)1097-0142(19990315)85:6<1269::aid-cncr8>3.0.co
https://doi.org/10.1002/(sici)1097-0142(19990315)85:6<1269::aid-cncr8>3.0.co
Autor:
Suzanne F. Jones, F. Anthony Greco, Howard A. Burris, David R. Spigel, James R. Rubinsak, Emily R. Burkett, Natalie R. Dickson, Melodie Thomas, Daniel C. Scullin, Joseph E. Brierre, Denise A. Yardley, John D. Hainsworth, James E. Bradof
Publikováno v:
Clinical lung cancer. 7(2)
BACKGROUND: Patients with advanced non–small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral agent that may benefit these patients. PATIENTS AND METHODS: Seventy-two patients with p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1741cf04deea854e4283a69b19ecd2c
https://pubmed.ncbi.nlm.nih.gov/16179100
https://pubmed.ncbi.nlm.nih.gov/16179100
Autor:
Don W. Shaffer, Burris Ha rd, Baker M, F A Greco, John D. Hainsworth, Joan B. Erland, Daniel C. Scullin
Publikováno v:
Cancer investigation. 21(2)
The purpose of the study was to evaluate the combination of gemcitabine and vinorelbine in the treatment of patients with relapsed or refractory small cell lung cancer. Between March 1998 and February 1999, 30 patients with relapsed or refractory sma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9e335074e6c9627424e9a54b5d5fc01
https://pubmed.ncbi.nlm.nih.gov/12743984
https://pubmed.ncbi.nlm.nih.gov/12743984
Autor:
Howard A. Burris, F. Anthony Greco, Jane Bramham, Sharon Calvert, Daniel C. Scullin, John D. Hainsworth, Noel T. Willcutt
Publikováno v:
Cancer investigation. 19(4)
The purpose of this study was to evaluate the activity of single-agent gemcitabine in previously treated patients with carcinoma of unknown primary site. Between January 1997 and October 1998, 39 patients were enrolled in this multicenter Phase II tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::676c0f4fafe3165b1d10116845868c1e
https://pubmed.ncbi.nlm.nih.gov/11405172
https://pubmed.ncbi.nlm.nih.gov/11405172
Autor:
James D. Bearden, C. E. McKay, D. A. Yardley, Sharlene Litchy, Gerry Ann Houston, David R. Spigel, H. A. Burris, John D. Hainsworth, Daniel C. Scullin, F. A. Greco
Publikováno v:
Journal of Clinical Oncology. 23:7123-7123
7123 Background: Adjuvant therapy with P (200mg/m2)/C (AUC=6) every 3 weeks for 4 cycles is associated with a 13% increase of survival in stage IB NSCLC patients (pts) (Late/breaking abstracts from...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::04f29f498827ad9aab8af56f8526ea8e
https://doi.org/10.1200/jco.2005.23.16_suppl.7123
https://doi.org/10.1200/jco.2005.23.16_suppl.7123
Autor:
Natalie R. Dickson, Suzanne F. Jones, Daniel C. Scullin, M. Thomas, John D. Hainsworth, F. A. Greco, James E. Bradof, D. A. Yardley, David R. Spigel, H. A. Burris
Publikováno v:
Journal of Clinical Oncology. 22:7086-7086
7086 Background: Gefitinib has single agent activity and excellent tolerability in patients (pts) with refractory non-small cell lung cancer (NSCLC) and may be of benefit to previously untreated poor performance status (PS) pts. Methods: The objectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f60765d215743bb8b70da7e14fe9607
https://doi.org/10.1200/jco.2004.22.90140.7086
https://doi.org/10.1200/jco.2004.22.90140.7086